MUSCAT GROUP 3Q Earnings Preview

3Q To Test M&A Synergy Monetisation And SG&A Discipline Under The Holding Company Structure

PublishedJanuary 30, 2026 at 10:00 GMT+9

Summary

Through 2Q, Revenue continued to trend higher on the back of M&A contributions, but earnings landed in the red due to front-loaded SG&A and higher interest expense. In 3Q, the key phase is whether acquired-brand PMI progress and “selection and concentration” into the brand-produce domain begin to show through in the P&L. With the October business reorganisation/share transfer and the late-October consolidation of Kanalabo as a subsidiary, the groundwork toward balancing Revenue growth and profitability has advanced. Near-term, goodwill and Interest-Bearing Debt are likely to keep rising; as such, this quarter puts the balance between capital efficiency and financial discipline at the centre of the investment case.

Key Points To Watch Next Quarter

Key Points & Focus	Implications
Profitability (P&L Inflection)Whether Operating Income turns profitable on a quarterly basis and SG&A control	If standalone 3Q Operating Income/Loss improves to within JPY △50M, confidence in achieving full-year adjusted EBITDA of JPY 350M rises. If improvement is limited, the market may view the payback phase for growth investment as being pushed out.
Revenue Growth (Top Line)9M Revenue progress versus the full-year plan	If 9M Revenue exceeds 75% of the full-year Revenue plan of JPY 4,470M (approx. JPY 3,353M), the risk of an overly 4Q-weighted delivery declines. If below 70%, the explanatory power of seasonality and the timing of newly consolidated contributions becomes critical.
M&A/PMI (Goodwill/Synergies)Rising goodwill amortisation burden and disclosure on PMI progress	Goodwill balance surged to JPY 2,110M as of 2Q, implying continued increases in amortisation expense. If PMI progress becomes more tangible and is accompanied by Gross Profit Margin improvement, tolerance for higher goodwill increases.
Financial Health (Capital Efficiency/Discipline)Trajectory of Equity Ratio and curbing growth in Interest-Bearing Debt	The Equity Ratio of 22.2% at 2Q end is in a declining trend. Even if additional borrowings continue in 3Q, this can be tolerated if the company demonstrates capital efficiency (invested capital turnover, monetisation). If the decline continues, financial constraints may cap the growth strategy.
Portfolio (Selection And Concentration)Post-restructuring Revenue mix and changes in profit contribution	Following the 10/15 business rationalisation and share transfer, resource concentration into priority areas is expected to start being reflected from 3Q. Even if non-core areas shrink, there is upside to the view if Gross Margin and fixed-cost efficiency improve.
Clinic Support/Oral Aesthetics (Quality Of Growth)Monetisation progress in the clinic support business and cross-sell	If the ramp-up from support to operations, cross-sell, and licensing rollout—key aims of consolidating Sukahanakai and MOM—can be confirmed, it would support a higher valuation as a medium-to-long-term LTV-type revenue stream.
Shareholder Value (ROE/ROIC Lens)Path to earnings recovery and disclosure of investment payback metrics	If 3Q advances disclosure of PMI KPIs (Gross Margin, ad efficiency, inventory turnover, etc.), the ROIC narrative gains credibility. If numerical disclosure remains limited, assessing the “quality” of growth becomes more difficult.

Key Issues Based On The Previous Results (FY2026/3 2Q Results)

In 1H, Revenue expanded to JPY 1,607M (+34.2% YoY), while SG&A rose to JPY 1,076M, driving Operating Income to an Operating Loss of JPY △203M. With the shift to a holding company structure and accelerated M&A, the company has secured growth in scale; in 3Q, the core debate is whether monetisation and integration benefits begin to materialise. On the balance sheet, Total Assets expanded to JPY 4,533M, while the Equity Ratio declined to 22.2%, underscoring that disciplined growth is now being tested.

1. Transition From M&A Expansion To A Monetisation Phase

Prior Period: Goodwill balance surged to 2,110M (2025/3-end 762M → 2025/9-end 2,110M); goodwill amortisation expanded to JPY 49M (JPY 21M in the prior-year period)
This Period: Confirm Gross Margin improvement from PMI, deceleration in SG&A growth, and the extent to which acquisition-related one-off costs are fading
Key Metrics: YoY change in goodwill amortisation, improvement in Gross Profit Margin (1H is approx. 54.3% based on Gross Profit of 873M), and a decline in SG&A ratio (1H is approx. 67.0%)

2. Correcting Front-Loaded SG&A And Narrowing Operating Losses

Prior Period: Against Revenue of 1,607M, SG&A was 1,076M, resulting in an Operating Loss of △203M (Operating Income was 17M in the prior-year period)
This Period: Balance continued brand/talent investment with optimisation of ROI, and reduce the quarterly loss magnitude
Key Metrics: Standalone 3Q Operating Income, YoY growth rate of SG&A, and the relationship between growth in advertising spend/personnel costs and Gross Profit expansion (within the disclosed scope)

3. Rising Interest Burden And Maintaining Financial Discipline

Prior Period: Interest expense increased to JPY 21M (JPY 5M in the prior-year period); short-term borrowings increased to JPY 610M (JPY 220M at 2025/3-end); long-term borrowings increased to JPY 1,346M (JPY 1,182M)
This Period: Explain how incremental borrowing links to payback from growth investments; assess capacity to absorb interest burden (earnings power to generate adjusted EBITDA)
Key Metrics: Pace of improvement in Recurring Profit (1H Recurring Loss was △216M), interest expense/Revenue ratio, and the pace of increases in Interest-Bearing Debt

4. Run-Rate Normalisation Of One-Off Costs From The Shift To A Holding Company Structure

Prior Period: Recorded 30M of “related costs such as the trade name change” as extraordinary loss; interim Net Loss before income taxes of △231M
This Period: Upside to earnings from fading one-offs; embed governance enhancement and the operating cadence of the group support structure
Key Metrics: Normalisation of extraordinary gains/losses, trend in non-operating expenses (1H 28M), and whether one-off items remain within SG&A

5. Improving Earnings Quality Through Business Reorganisation (Selection And Concentration)

Prior Period: As a material subsequent event, executed business reorganisation and transfer of a sub-subsidiary’s shares on 10/15; disclosed transfer price of JPY 420M and gain/loss on transfer of JPY 65M
This Period: Assess the impact of pruning non-core areas on fixed-cost efficiency in the P&L, and outcomes from concentrated investment into the brand-produce domain
Key Metrics: Simultaneous improvement in Revenue growth and margins from 3Q onward, whether restructuring-related gains/losses arise, and cash generation (improvement in operating CF)

Major Timely Disclosures This Fiscal Year

2025/12/23
Notice Regarding Execution of a Commitment-Type Term Loan Agreement with Financial Covenants - Securing a funding facility with built-in financial discipline increases agility for growth investment, while raising accountability for delivering the profit plan. Notice Regarding Execution of a Commitment-Type Term Loan Agreement with Financial Covenants
2025/11/28
FAQ (FY2026/3 2Q Results And Upward Revision To Guidance) - Supplementary disclosure on the background/assumptions behind the upward revision reduces investor uncertainty. The focus in 3Q is whether progress tracks the stated assumptions. FAQ (FY2026/3 2Q Results And Upward Revision To Guidance)
2025/11/14
Notice Regarding Revision of Full-Year Guidance - Set out full-year targets of Revenue JPY 4,470M, adjusted EBITDA JPY 350M, and adjusted Net Income JPY 218M, clarifying the intent to balance growth investment with monetisation. Achievement confidence in 3Q is likely to drive share price direction. Notice Regarding Revision of Full-Year Guidance
2025/11/14
Notice Regarding Recognition of Extraordinary Income Accompanying Change in a Consolidated Subsidiary (Share Transfer) - Signals progress in optimising the business portfolio. While extraordinary income provides near-term P&L uplift optionality, the key battleground for valuation is sustainable earnings uplift. Notice Regarding Recognition of Extraordinary Income Accompanying Change in a Consolidated Subsidiary (Share Transfer)

Prior Quarter Results (FY2026/3 2Q Actual)

The company operates the brand-produce business as a single segment, integrating a business model that combines brand expansion via M&A with SNS-driven sales and marketing support. In 2Q, the top line expanded due to the shift to a holding company structure and the consolidation of multiple new entities, while upfront costs—including integration and the organisational transition—pressured profits. Over the medium term, under a niche-top strategy, the focus is on expanding the brand portfolio, driving cross-sell, and improving profitability through operational efficiency.

Item	Amount	YoY	Versus Company Plan	Remarks
Revenue	JPY 1,607M	+34.2% YoY	-	Revenue growth trend supported by M&A contribution
Operating Income	JPY △203M	-	-	Front-loaded SG&A (SG&A 1,076M)
Recurring Profit	JPY △216M	-	-	Interest expense increased to 21M
Net Income	JPY △186M	-	-	Recorded 30M of “related costs such as the trade name change” as extraordinary loss
EPS	△62.41 yen	-	-	Average shares outstanding during the period: 2,985,587 shares

[Progress Versus Full-Year Plan: 35.9% (prior-year period: -)]